Searched for
LUPIN ONCOLOGY BLOCK
Most difficult: Staying invested in businesses while ignoring noise called Gulf war; 19 stocks from different sectors to ‘hold’Businesses that create long-term wealth are those where the demand runway is long, the competitive position is strong, and the management i...- Time to look & think beyond volatility: 6 large-caps stocks from different sectors with an upside potential of up to 30%While the mood of the market has turned bullish, volatility is ever-present. So, it is best to be always ready for it. And there is a high ...
- Stocks in news: Tata Steel, LG India, Honasa Consumer, SpiceJet, Hero MotoCorpIndian markets surged on Wednesday, buoyed by positive trade talks with the US and strong Q2 corporate earnings. Tata Steel reported a sign...
- Lupin unit commissions oncology block at Vizag plant to expand CDMO bizDrug firm Lupin has commissioned a new oncology block at its Vizag manufacturing plant. This dedicated unit will boost contract development...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of more than 25%The way things have panned out in the past couple of weeks, it is clear that the bulls are in no mood to leave the street anytime soon. At ...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of more than 27%After being relentless sellers for a large part of the calendar year 2025, FPI numbers for October have turned positive. This is the second...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of more than 25%The markets have a big element of probability. The way things have panned out in the past few weeks, it is very likely that the bulls will ...
- Mid-cap pharma space: Risk & opportunity are two sides of the same coin. 7 pharma stocks with upside potential of up to 41%Two things increase the probability of a sector becoming the next big sector in India. One: As a country, India should have some edge in th...
- Lupin in talks with Japan's Astellas, Shionogi to buy their off-patent drug brandsThe acquisition will result in a wider offering for Lupin in Japanese market where its sales last fiscal stood at Rs 1,364 crore.
- Cadila Healthcare to acquire Claris Lifesciences for Rs 3,400 croreBoth sides are currently engaged in last-minute due diligence negotiations involving tax and other financial matters, said at least five so...
Load More
